Predictive Oncology CEO Discusses Corporate Milestones, Unique Approach to Cancer Research in Exclusive Broadcast
November 19 2019 - 08:30AM
via NetworkNewsAudio – Predictive Oncology Inc. (NASDAQ: POAI), a
knowledge-driven precision medicine company focused on applying
data and artificial intelligence (AI) to personalized medicine and
drug discovery, today announces the broadcast of its audio
interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW)
solution that delivers clients unparalleled visibility, recognition
and brand awareness in the investment community.
The interview can be heard at http://nnw.fm/53oiD
Predictive Oncology CEO Dr. Carl Schwartz joins NNW’s Stuart
Smith for a look at the company’s strategy of applying its smart
tumor profiling and AI platform to extensive genomic and biomarker
patient data sets, allowing them to build predictive models of
tumor drug response that will improve clinical outcomes for the
cancer patients. The interview also digs into the company’s
numerous corporate and scientific milestones achieved in 2019.
“Predictive Oncology and its subsidiaries, in collaboration with
key players in the pharmaceutical, diagnostic and biotech
industries, are finding success in several arenas,” Dr. Schwartz
says. The Skyline Medical division continues to grow and expand
worldwide with sales of its direct-to-drain fluid disposal system,
designed specifically for medical applications, actively selling in
the Middle East, India, Australia, and in the United States.
The company’s TumorGenesis division has advanced its research to
the point where tumors can be grown outside of the body in a medium
that “fools the tumor into thinking it’s still in the body,” Dr.
Schwartz explains. The advantage to this method of research is that
it allows for a faster and more accurate identification of
biomarkers, which can lead to development of patient-specific
treatment options. Dr. Schwartz expects this revolutionary product
to hit the market by year’s end.
The company’s main division, Helomics, holds the world’s largest
database of tumor drug response profiles - over 150,000 tumors
covering more than 137 types of cancer gathered over the last 15
years. Helomics applies AI to this rich data to aid oncologists in
personalizing cancer therapy and to drive development of new,
targeted therapies. Collaborative studies are underway with several
renowned medical institutions and pharmaceutical firms to validate
Helomic’s AI platform for several targeted cancers.
“In contrast to other companies that are just starting to do
this, who then have to wait for at least four or five years to
obtain patient outcomes, we already have this information going
back over 10 years. This ability to access historical outcome data
to complement the drug response profiles and molecular information
about the tumor makes us unique,” Dr. Schwartz says. “I think that
we are looking forward to a robust 2020, with a lot more to come. I
would tell all of our shareholders to stay tuned.”
Listen to the full interview here: http://nnw.fm/53oiD
About Predictive Oncology Inc.
Predictive Oncology is an AI-driven company focused on applying
artificial intelligence to personalized medicine and drug
discovery. The company applies smart tumor profiling and its AI
platform to extensive genomic and biomarker patient data sets to
predict clinical outcomes and, most importantly, improve patient
outcomes for cancer patients of today and tomorrow. Predictive
Oncology currently has approximately 150,000 clinically validated
cases on its molecular information platform, with more than 38,000
specific to ovarian cancer. The company’s data is highly
differentiated, having both drug-response data and access to
historical outcome data from patients. Predictive Oncology intends
to generate additional sequence data from these tumor samples to
deliver on the clear unmet market need across the pharmaceutical
industry for a multi-omic approach to new drug development. For
more information, visit the company’s website
at www.Predictive-Oncology.com.
About NetworkNewsAudio
NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution, allows
you to sit back and listen to market updates, CEO interviews and a
Company AudioPressRelease (APR). These audio clips provide
snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York
www.NetworkNewsWire.com 212.418.1217 Office
Editor@NetworkWire.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2023 to Mar 2024